SlideShare a Scribd company logo
1 of 62
Download to read offline
Drug Discovery & Development
DR. KARUN KUMAR
JUNIOR RESIDENT – II
DEPT. OF PHARMACOLOGY
INTRODUCTION
Creation of a new drug involves :-
1. Drug discovery (Research) :- Identification of a
potential therapeutic target  Selection of a single
molecule for testing in humans.
2. Drug development (Development) :- Preclinical
studies that support initial clinical trials through
approval of the drug by regulatory authorities.
3. Commercialization (Marketing) :- Product 
Therapeutic application  Sales
Drug discovery and development
Drug discovery process
Process by which pharmaceutical, biotechnology,
academic & Govt. laboratories identify or screen
compounds to find potentially active therap. agents
Multidisciplinary nature of drug
discovery
Drug discovery process
Stages of
drug
discovery
Target identification
• Target  Molecular recognition site to which drug
binds
• Target may be
• Protein molecule
• A receptor
• Enzyme
• Transport molecule
• Ion channel
• Tubulin
• Immunophilin
Therapeutic drug targets
Strategies to find new drug targets
1. Conventional strategies
a) Analysis of pathophysiology
b) Analysis of MOA of existing drugs
2. New strategies
a) Disease genes
b) Disease-modifying genes
Disease genes
• Abl-kinase  Molecular target for Imatinib
• Secretase inhibitors  Anti-Alzheimer drugs
• Most promising field  Cancer therapies
• Identifying d/s gene  Valuable pointers to drug
targets
Disease modifying genes
• Most important category
• Approaches used :-
1. Gene expression profiling
2. Gene knockout studies
Gene expression profiling
Principle  Development of any disease phenotype
involves changes in gene expression in cells & tissues
involved
Method  DNA microarray (‘gene chips’)
DNA microarray
Cluster
analysis of
gene
expression
experiment
(Dendrogram)
Gene knockout screening
• Generation of transgenic ‘gene knockout’ strains of
mice
• Examples
1. Inactiv. Of gene for ACE/ATR  ↓ B.P.
2. Elim. Of gene encoding GABAA  Irrit. In mice
3. Cathepsin K  Osteoporosis
4. Melanocortin receptors  Obesity
• Flatworm & zebrafish  Speed up the process
Target validation
• Experimental approach by which a “potential” drug
target can be tested & given further credibility
• Main approach
• Pharmacological  mGluR for pain
• Genetic
• Antisense oligonuceotides
• RNA interference
• Transgenic animals
Phase D0  ‘Target identification’ (Research with
intent of identifying a therapeutic target)
Phase D1 + D2  ‘Lead identification’ (Initial
screening to discover chemical template for lead
optimization).Tests include HTS,LTS(in vitro & in vivo)
Phase D3  ‘Lead optimization’ (Optimiz. & biol.
Testing of compound).Outcome  Best in potency &
selectivity, as well as ADME properties
Phase D4  Completion of studies to allow 1st
application in man
Antisense Oligonucleotides
Stretches of RNA complementary to gene of interest
↓
Bind to cellular mRNA (Prevent its translation)
↓
Inhibits expression of specific genes
↓
Role of ‘specific genes’ in disease phenotype can be
determined
RNA interference
Short lengths of dsRNA (siRNAs)
↓
Activate RISC (RNA induced silencing complex)
↓
Destroys corresponding fmRNA in the cell
↓
Gene silenced
Transgenic animals
Important definitions
• Screening  Testing many compounds in assays
relevant to the disease in question
• Hit  A compound that passes such a ‘screen’
• Primary hit  Compound giving positive result in a
screening assay
• Confirmed hit  Compound is confirmed as
positive when assay is repeated
• Validated hit  Confirmed hit that shows selective
activity
• Lead compound  A new chemical entity that could be
developed in a new drug by optimizing beneficial
effects & minimizing S/E
Should comply with Lipinski’s rule of 5 :-
• Mol. Wt. < 500 Da cLogP < 5
• No. of H bond donors <5 Sum of no. of Ns & Os <10
• Drug candidate  End result of lead optimization (A
compound judged suitable for precl. & cl. Develop.)
• Development compound  Drug candidate that has
been accepted for further development
Screening
1. Selectivity screening  In vitro tests (If compound
is selective to merit further investigation)
2. Pharmacological profiling
• In vitro profiling  Study on isolated tissues has been
the mainstay
• In vivo profiling  Imaging technologies used
• MRI
• USG
• PET
• X-ray densitometry tomography
Animal models of disease
1. Acute physiological & pharmacological models
• Seizures induced by electrical stimulation of the
brain  Epilepsy
• Histamine induced bronchoconstriction  Asthma
• Eddy’s hot plate test  Pain
• Injection of LPS & cytokines  Septic shock
• Elevated plus maze test  Anxiolysis
2. Chronic physiological or
pharmacological models
• Use of Alloxan / Streptozotocin  Type I DM
• Inducing brain ischemia  Stroke
• Inducing coronary ischemia  IHD
• “Kindling”  Epilepsy
• Self-admin. of opiates/nicotine  Drug dependence
• Cholesterol fed rabbits  Hypercholesterolemia &
atherosclerosis
• Immunization with myelin basic protein  MS
• Admin. Of MPTP  Parkinson’s disease
• Transplant. Of malignant cells into immunodef.
Animals  Progressive tumors (Cancer)
3. Genetic models
1. SHR
2. Seizure-prone dogs
3. Rats insensitive to ADH
4. Obese mice
1. CF
2. DMD
3. Leptin gene (mutated in ob/ob mice)
5. Alzheimer’s disease (APP)
Validity criteria (Willner 1984)
1. Face validity  Accuracy with which model
reproduces the phenomena char. human d/s
2. Construct validity  Extent to which etiology of
human disease is reflected in model
3. Predictive validity  Extent to which
manipulation (drug t/t) is predictive of effects in
the human disorder
Identification of hits
1. Compound centered approach  Traditional
Compound is identified
↓
Biological profile is explored
↓
If compd. displays desirable pharmacologic activity
↓
Compound is refined & developed further
2. Target centered approach
Putative drug target (receptor/enzyme) is identified
↓
Researchers search for compounds which interact
with target (agonist/antagonist/modulator)
Search maybe:
1. Systematic  Uses info. About structure of target
as a starting point
2. Shotgun approach  All compounds in a large
library of substances are tested in a high-speed
automated assay
High-throughput screening
• Simplest target centered approach
• Uses a target based assay & robotic automation to
test thousands of compounds in a few days time
• 2 critical aspects :-
1. A large library of compounds must be available
for screening
2. Assay (Simple/sophisticated) that leads to rapid
identification of true hits must be developed
Lead identification
Library is “run through” the assay (96/384-well plate)
↓
‘Primary hits’ are examined more closely
↓
Further screening is done (To eliminate false positives
& false negatives)
↓
Leads are advanced in ‘lead optimization’ process
Lead optimization
Physical, chemical, biological & pharmacological
properties of promising lead molecules (that
appear to interact with the target in a desirable
way) are
Characterized & refined with the ultimate goal
Of selecting a single molecule to enter into
Clinical testing & formal drug development
Factors causing termination
1. Failure to demonstrate efficacy in a rigorous animal
model of human disease
2. Low bioavailability
3. Extensive/complex metabolism  Potentially
dangerous reactive metabolites
4. Toxic effects in preliminary animal toxicology studies
5. In vitro evidence that molecule may damage DNA
6. Extremely difficult chemical synthesis
Drug development
• All activities involved in transforming a compound from
drug candidate  Product approved for marketing by
appropriate regulatory authorities
• Falls in 3 main parts :-
1. Technical development  Ensuring quality of end-
product
2. Investigative studies  Safety & efficacy
3. Managerial functions  Co-ordination,
documentation & liaison with regulatory authorities
Stages of drug development
Stage No. of yrs.
Synthesis/isolation of compound 1-2
Preclinical studies (Scr.,eval.,pk. & short term
toxicity test. in animals)
2-4
Scrutiny & grant of permission for clinical trials 0.25-0.5
Pharmaceutical formulation, standardization of
chemical/biological/immuno-assay of the
compound
0.5-1
Clinical studies: Phase I,II,III trials; Long term
animal toxicity testing
3-10
Review & grant of marketing permission 0.5-2
Post-marketing surveillance No fixed
duration
Phases of Precl. & Clinical Development
Phase Primary goal Dose Patient monitor
Number of
participants
Preclinic
al
Testing of drug in non-
human subjects
Unrestricted
A graduate level
researcher-Ph.D.
In vitro & in vivo
animal models
Phase 0
Oral bioavailability & half-
life of drug
Subtherapeutic
Clinical
researcher
10 people
Phase I
Testing of drug on healthy
volunteers (safety)
Subtherapeutic
with asc. Doses
Clinical
researcher
20-100 people
Phase II
Testing of drug on patients
(efficacy & tolerability)
Therapeutic dose
Clinical
researcher
100-300 people
Phase III
Testing of drug on pts.
(confirm efficacy)
Therapeutic dose
Clinical research.
& Physician
1000-2000
people
Phase IV
Post-marketing
surveillance (A/E, D-D I)
Therapeutic dose Physician
Anyone seeking
treatment
Phase V Translational research No dosing None All reported use
DeMets D., Friedman L. and Furberg C.(2010).Fundamentals of Clinical Trials. Springer 4th Edition
Goodman and Gilman's The Pharmacological Basis of Therapeutics, (2011) 12th Edition
Preclinical development
Aim  Meet all requirements before a new compound is
deemed ready to be tested for the 1st time in humans
Work falls into :-
1. Safety pharmacology  Testing to check that drug
does not produce hazardous acute effects
2. Preliminary toxicological testing  Eliminate
genotoxicity & determine maximum non-toxic dose of
drug (given daily for 28 days & tested in 2 species)
1. Pharmacokinetic testing (ADME studies) in laboratory animals
2. Chemical & pharmaceutical dev
3. Pharmacokinetic testing (ADME studies) in
laboratory animals
4. Chemical & pharmaceutical development 
Assess feasibility of large scale synthesis &
purification
5. Assess stability of compound under various
conditions
6. Develop a formulation suitable for clinical studies
• Work done in accordance with GLP
IND
• New drug ready to be studied in humans  a
Notice of Claimed Investigational Exemption for a
New Drug (IND) must be filed with the FDA
• It includes :-
1. Info. on the composition and source of the drug
2. Chemical and manufacturing information
• Includes :-
1. Info. on the composition and source of the drug
2. Chemical and manufacturing information
3. All data from animal studies
4. Proposed plans for clinical trials
5. Names and credentials of physicians who will
conduct the clinical trials
6. A compilation of the key data relevant to study of
the drug in humans that has been made available
to investigators and their institutional review
boards
Phase 0 (Microdosing study)
• Developed by FDA & EMA as “cost-cutting” tools
Very low doses (1/100th of estimated human dose or
max. of 100 µg total dose of candidate drug) are
administered to healthy volunteers
↓
Pharmacok worked out using AMS with radiolabelled
drug/LC-MS to measure ultra low drug levels
• Subpharm. dose  No toxic / therapeutic eff. But
yields human pharmacokinetic information
• Elaborate animal studies & costly phase I human
trials could be avoided for candidate drugs
• Useful in more precise selection of doses for phase
I study
• They are promising & most regulatory authorities
are willing to allow & consider them
Phase I
• Studies carried out  Phase I clinics (All vital func. Are
measured & emergency/resuscitative facilities avail.)
• Clinical investigators  Clinical pharmacologists
• Trial subjects  Healthy volunteers (25-100)
• Objectives :-
1. Check for safety (Drug affects CV, hepatic or renal
functions adversely)
2. Check for tolerability (Drug produces unpleasant
symptoms like headache, nausea & vomiting)
1. 3.
2. 3.
3. Determine whether humans & animals show
significant pharmacokinetic differences
4. Determine a safe clinical dosage range in humans
(Common rule  Begin with 1/5th or 1/10th of
MTD in animals & calc. it for 70 kg body wt.)
5. Determine the pharmacokinetics of the drug in
humans (Whether deficiency in drug effect is due
to lack of absorption / faster elimination)
6. Detect any predictable toxicity
Pharmacokinetic parameters
1. Cmax  Peak drug &/or metabolite concentration
2. Tmax  Time to peak drug &/or metabolite conc.
3. AUC0-∞  Area under conc.-time curve e.p. to inf.
4. AUC0-T  AUC calc. to a specific time point T
5. T1/2  Time taken for level of drug to dec. by 1/2
6. VD  Volume of distr.
7. CL  Clearance
8. MRT  Mean residence time (Avg. time a drug
molecule rem. In body after rapid i.m. injection)
Dosing & blood sampling schedule
for phase I studies
Phase II
• Drug studied for 1st time in pts. with target disease
• Main purpose  Gather evidence that drug has
effects suggested by preclinical trials
• End points :-
1. Definitive end point (Measures drug effect
directly  Pain relief [analgesic])
2. Surrogate end point (Predictive of the definitive
end point  Reduction in tumor size[anticancer])
Phase IIa
• “Proof of concept”/ “Proof of claims”
• Preliminary evidence of efficacy & safety
• Up to 200 pts. are studied  Potential therapeutic
benefits & side effects are observed
• Establishment of dose range for more definitive
therapeutic trials in phase IIb
• Study design  Single blind (Subject unaware if he
is taking placebo/positive control/new drug)
Phase IIb
• Dose-finding studies
• To confirm efficacy with statistical significance
• Determine the optimal dose & dosing regimen
• Large no. of patients used (200-400)
• Study design  Double blind (3rd party holds the
code identifying each medication & this code is not
deciphered until all clinical data has been coll.)
Phase III
• Large scale, multicentered randomized double blind
trials to further establish safety & efficacy
• Made using “Double-blind cross over” designs to
minimize errors
• NDA  After completion of phase III trials,
sponsors file a “New Drug Application” with the
drug control authorities of that country
• NDS  If documentation is acceptable & in
compliance, drug enters market with NDS
Double blind Cross Over Design
Pt. grp.
(randomi
zed)
Week 1 Week 2 Week 3
I Standard
drug
Placebo New drug
II Placebo New drug Standard
drug
III New drug Standard
drug
Placebo
Phase IV
• Surveillance phase during the post marketing
clinical use of the drug
• Used to discover
• Relatively rare side effects
• Previously unknown drug interaction
• Previously unknown therapeutic use detected by a
chance discovery
Phase V
• Aims to bridge the gap between basic and clinical
research1
• Encompasses laboratory studies, clinical demands,
public health and health management, policies and
economics1
• Crucial in the evolution of contemporary
biomedical science1
• It is used to signify the integration of a new clinical
treatment into widespread public health practice2
1-Translational research: from benchside to bedside.N C Keramaris, N K Kanakaris, C Tzioupis, G Kontakis, P V Giannoudis
Academic Department of Trauma and Orthopaedics, Leeds Teaching Hospitals, University of Leeds, Great George Street,
Leeds LS1 3EX, UK.Injury (Impact Factor: 1.93). 07/2008; 39(6):643-50. DOI: 10.1016/j.injury.2008.01.051 Source: PubMed
2-Margaret A. Rogers (June 2009). "What are the phases of intervention research?". American Speech-Language-Hearing
Association. Retrieved Jan 8, 2013.
Preclinical safety assessment
1. Exploratory toxicology
• Rough estimate of toxicity (2 weeks)
• Provides an indication of main organs & physiological
systems involved
2. Regulatory toxicology (GLP)
• Reqd. by regulatory authorities/EC before compound
can be given for 1st time to humans
• Studies reqd. to support an application for marketing
approval
Timing of safety assessment
Genotoxicity
• Mutagenicity  Chemical alteration of DNA
sufficient to cause abnormal gene expression in the
affected cell & its offspring
• Chromosomal damage
• End results  Carcinogenesis & Teratogenicity
(detected by long-term animal studies)
Toxicokinetics
“Generation of pharmacokinetic data, either as an
integral component in the conduct of non-clinical
toxicity studies, or in specially designed supportive
studies, in order to assess systemic exposure” (ICH
Guideline S3A)
• Pharmacokinetics applied to toxicological studies
Toxicity measures
1. NTEL  Largest dose in most sensitive species
2. LD50  Estimated dose reqd. to kill 50% expt. An.
3. NOAEL  Largest dose causing neither tissue
toxicity nor undesirable physiological effects
4. MTD  Largest dose tested causing no obvious
signs of ill-health
5. NOEL  Threshold for producing any observed
pharmacological or toxic effect
THANK YOU

More Related Content

What's hot (20)

Pre Clinical Studies
Pre Clinical StudiesPre Clinical Studies
Pre Clinical Studies
 
Stages of drug discovery
Stages of drug discoveryStages of drug discovery
Stages of drug discovery
 
Preclinical development
Preclinical development Preclinical development
Preclinical development
 
drug discovery & development
drug discovery & developmentdrug discovery & development
drug discovery & development
 
High throughput screening
High throughput screening High throughput screening
High throughput screening
 
drug discovery- history, evolution and stages
drug discovery- history, evolution and stagesdrug discovery- history, evolution and stages
drug discovery- history, evolution and stages
 
various approaches to drug discovery
various approaches to drug discoveryvarious approaches to drug discovery
various approaches to drug discovery
 
Biosimilars
BiosimilarsBiosimilars
Biosimilars
 
Clinical Trial Phases
Clinical Trial PhasesClinical Trial Phases
Clinical Trial Phases
 
Drug discovery hit to lead
Drug discovery hit to leadDrug discovery hit to lead
Drug discovery hit to lead
 
Preclinical studies
Preclinical studiesPreclinical studies
Preclinical studies
 
Drug discovery and development process
Drug discovery and development processDrug discovery and development process
Drug discovery and development process
 
Schedule y
Schedule ySchedule y
Schedule y
 
Phases of clinical trials
Phases of clinical trialsPhases of clinical trials
Phases of clinical trials
 
Schedule y
Schedule ySchedule y
Schedule y
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
New drug development
New drug developmentNew drug development
New drug development
 
CONTRACT RESEARCH ORGANIZATION
CONTRACT RESEARCH ORGANIZATIONCONTRACT RESEARCH ORGANIZATION
CONTRACT RESEARCH ORGANIZATION
 
Drug discovery presentation
Drug discovery presentationDrug discovery presentation
Drug discovery presentation
 
1. An Overview of Drug Discovery Process.pdf
1. An Overview of Drug Discovery Process.pdf1. An Overview of Drug Discovery Process.pdf
1. An Overview of Drug Discovery Process.pdf
 

Viewers also liked

Presentation by MicroConstants at BIOCOM CRO event May 2013: Virtual Drug Dev...
Presentation by MicroConstants at BIOCOM CRO event May 2013: Virtual Drug Dev...Presentation by MicroConstants at BIOCOM CRO event May 2013: Virtual Drug Dev...
Presentation by MicroConstants at BIOCOM CRO event May 2013: Virtual Drug Dev...BIOCOMCRO
 
Investigational new drug application
Investigational new drug applicationInvestigational new drug application
Investigational new drug applicationGaurav Kr
 
Drug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templatesDrug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templatesSlideTeam.net
 
Metabolomics
MetabolomicsMetabolomics
Metabolomicspriya1111
 
Drug development and clinical trial phases
Drug development and clinical trial phasesDrug development and clinical trial phases
Drug development and clinical trial phasesSunil Boreddy Rx
 
Drugs approved in 2010
Drugs approved in 2010Drugs approved in 2010
Drugs approved in 2010Naveen Kumar
 
Steps involved in dosage development of new drug
Steps involved in dosage development of new drugSteps involved in dosage development of new drug
Steps involved in dosage development of new drugmadhuri muramshetty
 
New Drug Application [NDA]
New Drug Application [NDA]New Drug Application [NDA]
New Drug Application [NDA]Sagar Savale
 
PHARMACEUTICAL WASTE MANAGEMENT IN INDIA
PHARMACEUTICAL WASTE MANAGEMENT IN INDIAPHARMACEUTICAL WASTE MANAGEMENT IN INDIA
PHARMACEUTICAL WASTE MANAGEMENT IN INDIAAakashdeep Raval
 
Investigational new drug application new
Investigational new drug application newInvestigational new drug application new
Investigational new drug application newAakrati Gupta
 
New drug application
New drug applicationNew drug application
New drug applicationVKEkbote
 
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)Vamsikrishna Reddy
 
Pharmaceutical Waste Treatment and Disposal Practices
Pharmaceutical Waste Treatment and Disposal PracticesPharmaceutical Waste Treatment and Disposal Practices
Pharmaceutical Waste Treatment and Disposal Practicesrekhac86
 

Viewers also liked (18)

Presentation by MicroConstants at BIOCOM CRO event May 2013: Virtual Drug Dev...
Presentation by MicroConstants at BIOCOM CRO event May 2013: Virtual Drug Dev...Presentation by MicroConstants at BIOCOM CRO event May 2013: Virtual Drug Dev...
Presentation by MicroConstants at BIOCOM CRO event May 2013: Virtual Drug Dev...
 
Investigational new drug application
Investigational new drug applicationInvestigational new drug application
Investigational new drug application
 
Drug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templatesDrug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templates
 
Metabolomics
MetabolomicsMetabolomics
Metabolomics
 
Metabolomics
MetabolomicsMetabolomics
Metabolomics
 
Drug development and clinical trial phases
Drug development and clinical trial phasesDrug development and clinical trial phases
Drug development and clinical trial phases
 
Metabolomics
MetabolomicsMetabolomics
Metabolomics
 
Drugs approved in 2010
Drugs approved in 2010Drugs approved in 2010
Drugs approved in 2010
 
Nda ipr
Nda  iprNda  ipr
Nda ipr
 
Steps involved in dosage development of new drug
Steps involved in dosage development of new drugSteps involved in dosage development of new drug
Steps involved in dosage development of new drug
 
Drug Discovery New Drug Development Process
Drug Discovery New Drug Development ProcessDrug Discovery New Drug Development Process
Drug Discovery New Drug Development Process
 
New Drug Development Process
New Drug Development ProcessNew Drug Development Process
New Drug Development Process
 
New Drug Application [NDA]
New Drug Application [NDA]New Drug Application [NDA]
New Drug Application [NDA]
 
PHARMACEUTICAL WASTE MANAGEMENT IN INDIA
PHARMACEUTICAL WASTE MANAGEMENT IN INDIAPHARMACEUTICAL WASTE MANAGEMENT IN INDIA
PHARMACEUTICAL WASTE MANAGEMENT IN INDIA
 
Investigational new drug application new
Investigational new drug application newInvestigational new drug application new
Investigational new drug application new
 
New drug application
New drug applicationNew drug application
New drug application
 
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
 
Pharmaceutical Waste Treatment and Disposal Practices
Pharmaceutical Waste Treatment and Disposal PracticesPharmaceutical Waste Treatment and Disposal Practices
Pharmaceutical Waste Treatment and Disposal Practices
 

Similar to Drug discovery and development

Drug development process
Drug development processDrug development process
Drug development processKarthiga M
 
New Drug Discovery And Development (part-2)
New Drug Discovery And Development (part-2)New Drug Discovery And Development (part-2)
New Drug Discovery And Development (part-2)swatisejwani
 
1. Unit I - new drug discovery and development.
1. Unit I - new drug discovery and development.1. Unit I - new drug discovery and development.
1. Unit I - new drug discovery and development.Audumbar Mali
 
Phase clinicaltrial
Phase clinicaltrialPhase clinicaltrial
Phase clinicaltriallillibabu
 
PreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdfPreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdfsayedjannatfatema72
 
Clinical research overview
Clinical research overviewClinical research overview
Clinical research overviewAcri India
 
Clinical research Overview ppt
Clinical research Overview pptClinical research Overview ppt
Clinical research Overview pptAcri India
 
Natural products in drug discovery
Natural products in drug discoveryNatural products in drug discovery
Natural products in drug discoverySAKTHIVEL G
 
Introduction to pre clinical screening of drugs
Introduction to pre clinical screening of drugsIntroduction to pre clinical screening of drugs
Introduction to pre clinical screening of drugsKanthlal SK
 
A review on stages of drug development and alternative methods for animal stu...
A review on stages of drug development and alternative methods for animal stu...A review on stages of drug development and alternative methods for animal stu...
A review on stages of drug development and alternative methods for animal stu...Frinto Francis
 
DDS DRUGS AND DOSAGE FORMS-2020.ppt
DDS DRUGS AND DOSAGE FORMS-2020.pptDDS DRUGS AND DOSAGE FORMS-2020.ppt
DDS DRUGS AND DOSAGE FORMS-2020.pptFakhrulAhsan2
 
Preclinical testing - An intro
Preclinical testing -  An introPreclinical testing -  An intro
Preclinical testing - An introsamthamby79
 
Drug development process
Drug development process Drug development process
Drug development process Zobayer Hossain
 
Drug Development Process
Drug Development ProcessDrug Development Process
Drug Development ProcessTusharJ7
 
Drug Development Process
Drug Development ProcessDrug Development Process
Drug Development ProcessINDERGOHRI
 
Drug discovery By Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
Drug discovery By  Neelima Sharma WCC chennai,neelima.sharma60@gmail.comDrug discovery By  Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
Drug discovery By Neelima Sharma WCC chennai,neelima.sharma60@gmail.comNeelima Sharma
 
New drug discovery
New drug discoveryNew drug discovery
New drug discoveryRashadKafeel
 
Drug discovery infoghraph
Drug discovery infoghraphDrug discovery infoghraph
Drug discovery infoghraphAmit mishra
 
All you have to know about drugs
All you have to know about drugsAll you have to know about drugs
All you have to know about drugsgoogle
 

Similar to Drug discovery and development (20)

Drug development process
Drug development processDrug development process
Drug development process
 
New Drug Discovery And Development (part-2)
New Drug Discovery And Development (part-2)New Drug Discovery And Development (part-2)
New Drug Discovery And Development (part-2)
 
1. Unit I - new drug discovery and development.
1. Unit I - new drug discovery and development.1. Unit I - new drug discovery and development.
1. Unit I - new drug discovery and development.
 
Phase clinicaltrial
Phase clinicaltrialPhase clinicaltrial
Phase clinicaltrial
 
PreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdfPreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdf
 
Clinical research overview
Clinical research overviewClinical research overview
Clinical research overview
 
Clinical research Overview ppt
Clinical research Overview pptClinical research Overview ppt
Clinical research Overview ppt
 
Natural products in drug discovery
Natural products in drug discoveryNatural products in drug discovery
Natural products in drug discovery
 
Drug discovery
Drug discoveryDrug discovery
Drug discovery
 
Introduction to pre clinical screening of drugs
Introduction to pre clinical screening of drugsIntroduction to pre clinical screening of drugs
Introduction to pre clinical screening of drugs
 
A review on stages of drug development and alternative methods for animal stu...
A review on stages of drug development and alternative methods for animal stu...A review on stages of drug development and alternative methods for animal stu...
A review on stages of drug development and alternative methods for animal stu...
 
DDS DRUGS AND DOSAGE FORMS-2020.ppt
DDS DRUGS AND DOSAGE FORMS-2020.pptDDS DRUGS AND DOSAGE FORMS-2020.ppt
DDS DRUGS AND DOSAGE FORMS-2020.ppt
 
Preclinical testing - An intro
Preclinical testing -  An introPreclinical testing -  An intro
Preclinical testing - An intro
 
Drug development process
Drug development process Drug development process
Drug development process
 
Drug Development Process
Drug Development ProcessDrug Development Process
Drug Development Process
 
Drug Development Process
Drug Development ProcessDrug Development Process
Drug Development Process
 
Drug discovery By Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
Drug discovery By  Neelima Sharma WCC chennai,neelima.sharma60@gmail.comDrug discovery By  Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
Drug discovery By Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
 
New drug discovery
New drug discoveryNew drug discovery
New drug discovery
 
Drug discovery infoghraph
Drug discovery infoghraphDrug discovery infoghraph
Drug discovery infoghraph
 
All you have to know about drugs
All you have to know about drugsAll you have to know about drugs
All you have to know about drugs
 

More from Karun Kumar

Drugs for Type 2 DM 6.6.23.pptx
Drugs for Type 2 DM 6.6.23.pptxDrugs for Type 2 DM 6.6.23.pptx
Drugs for Type 2 DM 6.6.23.pptxKarun Kumar
 
AMA General considerations 12.6.23.pptx
AMA General considerations 12.6.23.pptxAMA General considerations 12.6.23.pptx
AMA General considerations 12.6.23.pptxKarun Kumar
 
Drugs affecting blood
Drugs affecting blood Drugs affecting blood
Drugs affecting blood Karun Kumar
 
Drugs & Aids with specific applications in dental
Drugs & Aids with specific applications in dentalDrugs & Aids with specific applications in dental
Drugs & Aids with specific applications in dentalKarun Kumar
 
Cardiovascular system drugs
Cardiovascular system drugsCardiovascular system drugs
Cardiovascular system drugsKarun Kumar
 
Anti-viral drugs
Anti-viral drugsAnti-viral drugs
Anti-viral drugsKarun Kumar
 
Anti-TB & anti leprosy drugs
Anti-TB & anti leprosy drugs Anti-TB & anti leprosy drugs
Anti-TB & anti leprosy drugs Karun Kumar
 
Antiseptics, Disinfectants
Antiseptics, Disinfectants Antiseptics, Disinfectants
Antiseptics, Disinfectants Karun Kumar
 
Antiprotozoal drugs
Antiprotozoal drugsAntiprotozoal drugs
Antiprotozoal drugsKarun Kumar
 
Anti-fungal drugs
Anti-fungal drugsAnti-fungal drugs
Anti-fungal drugsKarun Kumar
 
Anti-cancer drugs
Anti-cancer drugsAnti-cancer drugs
Anti-cancer drugsKarun Kumar
 
Autonomic nervous system-III
Autonomic nervous system-IIIAutonomic nervous system-III
Autonomic nervous system-IIIKarun Kumar
 
Autonomic nervous system-II
Autonomic nervous system-II Autonomic nervous system-II
Autonomic nervous system-II Karun Kumar
 
Autonomic nervous system-I
Autonomic nervous system-IAutonomic nervous system-I
Autonomic nervous system-IKarun Kumar
 
AETCOM (Attitude, Ethics and Communication module)
AETCOM (Attitude, Ethics and Communication module)AETCOM (Attitude, Ethics and Communication module)
AETCOM (Attitude, Ethics and Communication module)Karun Kumar
 

More from Karun Kumar (20)

Drugs for Type 2 DM 6.6.23.pptx
Drugs for Type 2 DM 6.6.23.pptxDrugs for Type 2 DM 6.6.23.pptx
Drugs for Type 2 DM 6.6.23.pptx
 
AMA General considerations 12.6.23.pptx
AMA General considerations 12.6.23.pptxAMA General considerations 12.6.23.pptx
AMA General considerations 12.6.23.pptx
 
GA & SMR
GA & SMRGA & SMR
GA & SMR
 
Drugs affecting blood
Drugs affecting blood Drugs affecting blood
Drugs affecting blood
 
Drugs & Aids with specific applications in dental
Drugs & Aids with specific applications in dentalDrugs & Aids with specific applications in dental
Drugs & Aids with specific applications in dental
 
Diuretics
Diuretics Diuretics
Diuretics
 
Cardiovascular system drugs
Cardiovascular system drugsCardiovascular system drugs
Cardiovascular system drugs
 
CNS part 2
CNS part 2 CNS part 2
CNS part 2
 
CNS part 1
CNS part 1CNS part 1
CNS part 1
 
Autacoids
Autacoids Autacoids
Autacoids
 
Anti-viral drugs
Anti-viral drugsAnti-viral drugs
Anti-viral drugs
 
Anti-TB & anti leprosy drugs
Anti-TB & anti leprosy drugs Anti-TB & anti leprosy drugs
Anti-TB & anti leprosy drugs
 
Antiseptics, Disinfectants
Antiseptics, Disinfectants Antiseptics, Disinfectants
Antiseptics, Disinfectants
 
Antiprotozoal drugs
Antiprotozoal drugsAntiprotozoal drugs
Antiprotozoal drugs
 
Anti-fungal drugs
Anti-fungal drugsAnti-fungal drugs
Anti-fungal drugs
 
Anti-cancer drugs
Anti-cancer drugsAnti-cancer drugs
Anti-cancer drugs
 
Autonomic nervous system-III
Autonomic nervous system-IIIAutonomic nervous system-III
Autonomic nervous system-III
 
Autonomic nervous system-II
Autonomic nervous system-II Autonomic nervous system-II
Autonomic nervous system-II
 
Autonomic nervous system-I
Autonomic nervous system-IAutonomic nervous system-I
Autonomic nervous system-I
 
AETCOM (Attitude, Ethics and Communication module)
AETCOM (Attitude, Ethics and Communication module)AETCOM (Attitude, Ethics and Communication module)
AETCOM (Attitude, Ethics and Communication module)
 

Recently uploaded

Plant Tissue culture., Plasticity, Totipotency, pptx
Plant Tissue culture., Plasticity, Totipotency, pptxPlant Tissue culture., Plasticity, Totipotency, pptx
Plant Tissue culture., Plasticity, Totipotency, pptxHimansu10
 
LEAD6001 - Introduction to Advanced Stud
LEAD6001 - Introduction to Advanced StudLEAD6001 - Introduction to Advanced Stud
LEAD6001 - Introduction to Advanced StudDr. Bruce A. Johnson
 
Research Methodology and Tips on Better Research
Research Methodology and Tips on Better ResearchResearch Methodology and Tips on Better Research
Research Methodology and Tips on Better ResearchRushdi Shams
 
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdf
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdfPHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdf
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdfSumit Tiwari
 
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYS
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYSDLL Catch Up Friday March 22.docx CATCH UP FRIDAYS
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYSTeacherNicaPrintable
 
LEAD5623 The Economics of Community Coll
LEAD5623 The Economics of Community CollLEAD5623 The Economics of Community Coll
LEAD5623 The Economics of Community CollDr. Bruce A. Johnson
 
Arti Languages Pre Seed Send Ahead Pitchdeck 2024.pdf
Arti Languages Pre Seed Send Ahead Pitchdeck 2024.pdfArti Languages Pre Seed Send Ahead Pitchdeck 2024.pdf
Arti Languages Pre Seed Send Ahead Pitchdeck 2024.pdfwill854175
 
30-de-thi-vao-lop-10-mon-tieng-anh-co-dap-an.doc
30-de-thi-vao-lop-10-mon-tieng-anh-co-dap-an.doc30-de-thi-vao-lop-10-mon-tieng-anh-co-dap-an.doc
30-de-thi-vao-lop-10-mon-tieng-anh-co-dap-an.docdieu18
 
3.12.24 The Social Construction of Gender.pptx
3.12.24 The Social Construction of Gender.pptx3.12.24 The Social Construction of Gender.pptx
3.12.24 The Social Construction of Gender.pptxmary850239
 
UNIT I Design Thinking and Explore.pptx
UNIT I  Design Thinking and Explore.pptxUNIT I  Design Thinking and Explore.pptx
UNIT I Design Thinking and Explore.pptxGOWSIKRAJA PALANISAMY
 
Auchitya Theory by Kshemendra Indian Poetics
Auchitya Theory by Kshemendra Indian PoeticsAuchitya Theory by Kshemendra Indian Poetics
Auchitya Theory by Kshemendra Indian PoeticsDhatriParmar
 
2024.03.16 How to write better quality materials for your learners ELTABB San...
2024.03.16 How to write better quality materials for your learners ELTABB San...2024.03.16 How to write better quality materials for your learners ELTABB San...
2024.03.16 How to write better quality materials for your learners ELTABB San...Sandy Millin
 
2024 March 11, Telehealth Billing- Current Telehealth CPT Codes & Telehealth ...
2024 March 11, Telehealth Billing- Current Telehealth CPT Codes & Telehealth ...2024 March 11, Telehealth Billing- Current Telehealth CPT Codes & Telehealth ...
2024 March 11, Telehealth Billing- Current Telehealth CPT Codes & Telehealth ...Marlene Maheu
 
Alamkara theory by Bhamaha Indian Poetics (1).pptx
Alamkara theory by Bhamaha Indian Poetics (1).pptxAlamkara theory by Bhamaha Indian Poetics (1).pptx
Alamkara theory by Bhamaha Indian Poetics (1).pptxDhatriParmar
 
3.14.24 Gender Discrimination and Gender Inequity.pptx
3.14.24 Gender Discrimination and Gender Inequity.pptx3.14.24 Gender Discrimination and Gender Inequity.pptx
3.14.24 Gender Discrimination and Gender Inequity.pptxmary850239
 
Metabolism , Metabolic Fate& disorders of cholesterol.pptx
Metabolism , Metabolic Fate& disorders of cholesterol.pptxMetabolism , Metabolic Fate& disorders of cholesterol.pptx
Metabolism , Metabolic Fate& disorders of cholesterol.pptxDr. Santhosh Kumar. N
 
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...AKSHAYMAGAR17
 
The First National K12 TUG March 6 2024.pdf
The First National K12 TUG March 6 2024.pdfThe First National K12 TUG March 6 2024.pdf
The First National K12 TUG March 6 2024.pdfdogden2
 

Recently uploaded (20)

Plant Tissue culture., Plasticity, Totipotency, pptx
Plant Tissue culture., Plasticity, Totipotency, pptxPlant Tissue culture., Plasticity, Totipotency, pptx
Plant Tissue culture., Plasticity, Totipotency, pptx
 
LEAD6001 - Introduction to Advanced Stud
LEAD6001 - Introduction to Advanced StudLEAD6001 - Introduction to Advanced Stud
LEAD6001 - Introduction to Advanced Stud
 
Research Methodology and Tips on Better Research
Research Methodology and Tips on Better ResearchResearch Methodology and Tips on Better Research
Research Methodology and Tips on Better Research
 
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdf
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdfPHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdf
PHARMACOGNOSY CHAPTER NO 5 CARMINATIVES AND G.pdf
 
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYS
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYSDLL Catch Up Friday March 22.docx CATCH UP FRIDAYS
DLL Catch Up Friday March 22.docx CATCH UP FRIDAYS
 
t-test Parametric test Biostatics and Research Methodology
t-test Parametric test Biostatics and Research Methodologyt-test Parametric test Biostatics and Research Methodology
t-test Parametric test Biostatics and Research Methodology
 
LEAD5623 The Economics of Community Coll
LEAD5623 The Economics of Community CollLEAD5623 The Economics of Community Coll
LEAD5623 The Economics of Community Coll
 
Arti Languages Pre Seed Send Ahead Pitchdeck 2024.pdf
Arti Languages Pre Seed Send Ahead Pitchdeck 2024.pdfArti Languages Pre Seed Send Ahead Pitchdeck 2024.pdf
Arti Languages Pre Seed Send Ahead Pitchdeck 2024.pdf
 
30-de-thi-vao-lop-10-mon-tieng-anh-co-dap-an.doc
30-de-thi-vao-lop-10-mon-tieng-anh-co-dap-an.doc30-de-thi-vao-lop-10-mon-tieng-anh-co-dap-an.doc
30-de-thi-vao-lop-10-mon-tieng-anh-co-dap-an.doc
 
3.12.24 The Social Construction of Gender.pptx
3.12.24 The Social Construction of Gender.pptx3.12.24 The Social Construction of Gender.pptx
3.12.24 The Social Construction of Gender.pptx
 
UNIT I Design Thinking and Explore.pptx
UNIT I  Design Thinking and Explore.pptxUNIT I  Design Thinking and Explore.pptx
UNIT I Design Thinking and Explore.pptx
 
Auchitya Theory by Kshemendra Indian Poetics
Auchitya Theory by Kshemendra Indian PoeticsAuchitya Theory by Kshemendra Indian Poetics
Auchitya Theory by Kshemendra Indian Poetics
 
ANOVA Parametric test: Biostatics and Research Methodology
ANOVA Parametric test: Biostatics and Research MethodologyANOVA Parametric test: Biostatics and Research Methodology
ANOVA Parametric test: Biostatics and Research Methodology
 
2024.03.16 How to write better quality materials for your learners ELTABB San...
2024.03.16 How to write better quality materials for your learners ELTABB San...2024.03.16 How to write better quality materials for your learners ELTABB San...
2024.03.16 How to write better quality materials for your learners ELTABB San...
 
2024 March 11, Telehealth Billing- Current Telehealth CPT Codes & Telehealth ...
2024 March 11, Telehealth Billing- Current Telehealth CPT Codes & Telehealth ...2024 March 11, Telehealth Billing- Current Telehealth CPT Codes & Telehealth ...
2024 March 11, Telehealth Billing- Current Telehealth CPT Codes & Telehealth ...
 
Alamkara theory by Bhamaha Indian Poetics (1).pptx
Alamkara theory by Bhamaha Indian Poetics (1).pptxAlamkara theory by Bhamaha Indian Poetics (1).pptx
Alamkara theory by Bhamaha Indian Poetics (1).pptx
 
3.14.24 Gender Discrimination and Gender Inequity.pptx
3.14.24 Gender Discrimination and Gender Inequity.pptx3.14.24 Gender Discrimination and Gender Inequity.pptx
3.14.24 Gender Discrimination and Gender Inequity.pptx
 
Metabolism , Metabolic Fate& disorders of cholesterol.pptx
Metabolism , Metabolic Fate& disorders of cholesterol.pptxMetabolism , Metabolic Fate& disorders of cholesterol.pptx
Metabolism , Metabolic Fate& disorders of cholesterol.pptx
 
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...
DNA and RNA , Structure, Functions, Types, difference, Similarities, Protein ...
 
The First National K12 TUG March 6 2024.pdf
The First National K12 TUG March 6 2024.pdfThe First National K12 TUG March 6 2024.pdf
The First National K12 TUG March 6 2024.pdf
 

Drug discovery and development

  • 1. Drug Discovery & Development DR. KARUN KUMAR JUNIOR RESIDENT – II DEPT. OF PHARMACOLOGY
  • 2. INTRODUCTION Creation of a new drug involves :- 1. Drug discovery (Research) :- Identification of a potential therapeutic target  Selection of a single molecule for testing in humans. 2. Drug development (Development) :- Preclinical studies that support initial clinical trials through approval of the drug by regulatory authorities. 3. Commercialization (Marketing) :- Product  Therapeutic application  Sales
  • 4. Drug discovery process Process by which pharmaceutical, biotechnology, academic & Govt. laboratories identify or screen compounds to find potentially active therap. agents
  • 8. Target identification • Target  Molecular recognition site to which drug binds • Target may be • Protein molecule • A receptor • Enzyme • Transport molecule • Ion channel • Tubulin • Immunophilin
  • 10. Strategies to find new drug targets 1. Conventional strategies a) Analysis of pathophysiology b) Analysis of MOA of existing drugs 2. New strategies a) Disease genes b) Disease-modifying genes
  • 11. Disease genes • Abl-kinase  Molecular target for Imatinib • Secretase inhibitors  Anti-Alzheimer drugs • Most promising field  Cancer therapies • Identifying d/s gene  Valuable pointers to drug targets
  • 12. Disease modifying genes • Most important category • Approaches used :- 1. Gene expression profiling 2. Gene knockout studies
  • 13. Gene expression profiling Principle  Development of any disease phenotype involves changes in gene expression in cells & tissues involved Method  DNA microarray (‘gene chips’)
  • 16. Gene knockout screening • Generation of transgenic ‘gene knockout’ strains of mice • Examples 1. Inactiv. Of gene for ACE/ATR  ↓ B.P. 2. Elim. Of gene encoding GABAA  Irrit. In mice 3. Cathepsin K  Osteoporosis 4. Melanocortin receptors  Obesity • Flatworm & zebrafish  Speed up the process
  • 17. Target validation • Experimental approach by which a “potential” drug target can be tested & given further credibility • Main approach • Pharmacological  mGluR for pain • Genetic • Antisense oligonuceotides • RNA interference • Transgenic animals
  • 18. Phase D0  ‘Target identification’ (Research with intent of identifying a therapeutic target) Phase D1 + D2  ‘Lead identification’ (Initial screening to discover chemical template for lead optimization).Tests include HTS,LTS(in vitro & in vivo) Phase D3  ‘Lead optimization’ (Optimiz. & biol. Testing of compound).Outcome  Best in potency & selectivity, as well as ADME properties Phase D4  Completion of studies to allow 1st application in man
  • 19. Antisense Oligonucleotides Stretches of RNA complementary to gene of interest ↓ Bind to cellular mRNA (Prevent its translation) ↓ Inhibits expression of specific genes ↓ Role of ‘specific genes’ in disease phenotype can be determined
  • 20. RNA interference Short lengths of dsRNA (siRNAs) ↓ Activate RISC (RNA induced silencing complex) ↓ Destroys corresponding fmRNA in the cell ↓ Gene silenced
  • 22. Important definitions • Screening  Testing many compounds in assays relevant to the disease in question • Hit  A compound that passes such a ‘screen’ • Primary hit  Compound giving positive result in a screening assay • Confirmed hit  Compound is confirmed as positive when assay is repeated • Validated hit  Confirmed hit that shows selective activity
  • 23. • Lead compound  A new chemical entity that could be developed in a new drug by optimizing beneficial effects & minimizing S/E Should comply with Lipinski’s rule of 5 :- • Mol. Wt. < 500 Da cLogP < 5 • No. of H bond donors <5 Sum of no. of Ns & Os <10 • Drug candidate  End result of lead optimization (A compound judged suitable for precl. & cl. Develop.) • Development compound  Drug candidate that has been accepted for further development
  • 24. Screening 1. Selectivity screening  In vitro tests (If compound is selective to merit further investigation) 2. Pharmacological profiling • In vitro profiling  Study on isolated tissues has been the mainstay • In vivo profiling  Imaging technologies used • MRI • USG • PET • X-ray densitometry tomography
  • 25. Animal models of disease 1. Acute physiological & pharmacological models • Seizures induced by electrical stimulation of the brain  Epilepsy • Histamine induced bronchoconstriction  Asthma • Eddy’s hot plate test  Pain • Injection of LPS & cytokines  Septic shock • Elevated plus maze test  Anxiolysis
  • 26. 2. Chronic physiological or pharmacological models • Use of Alloxan / Streptozotocin  Type I DM • Inducing brain ischemia  Stroke • Inducing coronary ischemia  IHD • “Kindling”  Epilepsy • Self-admin. of opiates/nicotine  Drug dependence
  • 27. • Cholesterol fed rabbits  Hypercholesterolemia & atherosclerosis • Immunization with myelin basic protein  MS • Admin. Of MPTP  Parkinson’s disease • Transplant. Of malignant cells into immunodef. Animals  Progressive tumors (Cancer)
  • 28. 3. Genetic models 1. SHR 2. Seizure-prone dogs 3. Rats insensitive to ADH 4. Obese mice 1. CF 2. DMD 3. Leptin gene (mutated in ob/ob mice) 5. Alzheimer’s disease (APP)
  • 29. Validity criteria (Willner 1984) 1. Face validity  Accuracy with which model reproduces the phenomena char. human d/s 2. Construct validity  Extent to which etiology of human disease is reflected in model 3. Predictive validity  Extent to which manipulation (drug t/t) is predictive of effects in the human disorder
  • 30. Identification of hits 1. Compound centered approach  Traditional Compound is identified ↓ Biological profile is explored ↓ If compd. displays desirable pharmacologic activity ↓ Compound is refined & developed further
  • 31. 2. Target centered approach Putative drug target (receptor/enzyme) is identified ↓ Researchers search for compounds which interact with target (agonist/antagonist/modulator) Search maybe: 1. Systematic  Uses info. About structure of target as a starting point 2. Shotgun approach  All compounds in a large library of substances are tested in a high-speed automated assay
  • 32. High-throughput screening • Simplest target centered approach • Uses a target based assay & robotic automation to test thousands of compounds in a few days time • 2 critical aspects :- 1. A large library of compounds must be available for screening 2. Assay (Simple/sophisticated) that leads to rapid identification of true hits must be developed
  • 33. Lead identification Library is “run through” the assay (96/384-well plate) ↓ ‘Primary hits’ are examined more closely ↓ Further screening is done (To eliminate false positives & false negatives) ↓ Leads are advanced in ‘lead optimization’ process
  • 34. Lead optimization Physical, chemical, biological & pharmacological properties of promising lead molecules (that appear to interact with the target in a desirable way) are Characterized & refined with the ultimate goal Of selecting a single molecule to enter into Clinical testing & formal drug development
  • 35. Factors causing termination 1. Failure to demonstrate efficacy in a rigorous animal model of human disease 2. Low bioavailability 3. Extensive/complex metabolism  Potentially dangerous reactive metabolites 4. Toxic effects in preliminary animal toxicology studies 5. In vitro evidence that molecule may damage DNA 6. Extremely difficult chemical synthesis
  • 37. • All activities involved in transforming a compound from drug candidate  Product approved for marketing by appropriate regulatory authorities • Falls in 3 main parts :- 1. Technical development  Ensuring quality of end- product 2. Investigative studies  Safety & efficacy 3. Managerial functions  Co-ordination, documentation & liaison with regulatory authorities
  • 38. Stages of drug development Stage No. of yrs. Synthesis/isolation of compound 1-2 Preclinical studies (Scr.,eval.,pk. & short term toxicity test. in animals) 2-4 Scrutiny & grant of permission for clinical trials 0.25-0.5 Pharmaceutical formulation, standardization of chemical/biological/immuno-assay of the compound 0.5-1 Clinical studies: Phase I,II,III trials; Long term animal toxicity testing 3-10 Review & grant of marketing permission 0.5-2 Post-marketing surveillance No fixed duration
  • 39. Phases of Precl. & Clinical Development Phase Primary goal Dose Patient monitor Number of participants Preclinic al Testing of drug in non- human subjects Unrestricted A graduate level researcher-Ph.D. In vitro & in vivo animal models Phase 0 Oral bioavailability & half- life of drug Subtherapeutic Clinical researcher 10 people Phase I Testing of drug on healthy volunteers (safety) Subtherapeutic with asc. Doses Clinical researcher 20-100 people Phase II Testing of drug on patients (efficacy & tolerability) Therapeutic dose Clinical researcher 100-300 people Phase III Testing of drug on pts. (confirm efficacy) Therapeutic dose Clinical research. & Physician 1000-2000 people Phase IV Post-marketing surveillance (A/E, D-D I) Therapeutic dose Physician Anyone seeking treatment Phase V Translational research No dosing None All reported use DeMets D., Friedman L. and Furberg C.(2010).Fundamentals of Clinical Trials. Springer 4th Edition Goodman and Gilman's The Pharmacological Basis of Therapeutics, (2011) 12th Edition
  • 40. Preclinical development Aim  Meet all requirements before a new compound is deemed ready to be tested for the 1st time in humans Work falls into :- 1. Safety pharmacology  Testing to check that drug does not produce hazardous acute effects 2. Preliminary toxicological testing  Eliminate genotoxicity & determine maximum non-toxic dose of drug (given daily for 28 days & tested in 2 species)
  • 41. 1. Pharmacokinetic testing (ADME studies) in laboratory animals 2. Chemical & pharmaceutical dev 3. Pharmacokinetic testing (ADME studies) in laboratory animals 4. Chemical & pharmaceutical development  Assess feasibility of large scale synthesis & purification 5. Assess stability of compound under various conditions 6. Develop a formulation suitable for clinical studies • Work done in accordance with GLP
  • 42. IND • New drug ready to be studied in humans  a Notice of Claimed Investigational Exemption for a New Drug (IND) must be filed with the FDA • It includes :- 1. Info. on the composition and source of the drug 2. Chemical and manufacturing information
  • 43. • Includes :- 1. Info. on the composition and source of the drug 2. Chemical and manufacturing information 3. All data from animal studies 4. Proposed plans for clinical trials 5. Names and credentials of physicians who will conduct the clinical trials 6. A compilation of the key data relevant to study of the drug in humans that has been made available to investigators and their institutional review boards
  • 44. Phase 0 (Microdosing study) • Developed by FDA & EMA as “cost-cutting” tools Very low doses (1/100th of estimated human dose or max. of 100 µg total dose of candidate drug) are administered to healthy volunteers ↓ Pharmacok worked out using AMS with radiolabelled drug/LC-MS to measure ultra low drug levels
  • 45. • Subpharm. dose  No toxic / therapeutic eff. But yields human pharmacokinetic information • Elaborate animal studies & costly phase I human trials could be avoided for candidate drugs • Useful in more precise selection of doses for phase I study • They are promising & most regulatory authorities are willing to allow & consider them
  • 46. Phase I • Studies carried out  Phase I clinics (All vital func. Are measured & emergency/resuscitative facilities avail.) • Clinical investigators  Clinical pharmacologists • Trial subjects  Healthy volunteers (25-100) • Objectives :- 1. Check for safety (Drug affects CV, hepatic or renal functions adversely) 2. Check for tolerability (Drug produces unpleasant symptoms like headache, nausea & vomiting)
  • 47. 1. 3. 2. 3. 3. Determine whether humans & animals show significant pharmacokinetic differences 4. Determine a safe clinical dosage range in humans (Common rule  Begin with 1/5th or 1/10th of MTD in animals & calc. it for 70 kg body wt.) 5. Determine the pharmacokinetics of the drug in humans (Whether deficiency in drug effect is due to lack of absorption / faster elimination) 6. Detect any predictable toxicity
  • 48. Pharmacokinetic parameters 1. Cmax  Peak drug &/or metabolite concentration 2. Tmax  Time to peak drug &/or metabolite conc. 3. AUC0-∞  Area under conc.-time curve e.p. to inf. 4. AUC0-T  AUC calc. to a specific time point T 5. T1/2  Time taken for level of drug to dec. by 1/2 6. VD  Volume of distr. 7. CL  Clearance 8. MRT  Mean residence time (Avg. time a drug molecule rem. In body after rapid i.m. injection)
  • 49. Dosing & blood sampling schedule for phase I studies
  • 50. Phase II • Drug studied for 1st time in pts. with target disease • Main purpose  Gather evidence that drug has effects suggested by preclinical trials • End points :- 1. Definitive end point (Measures drug effect directly  Pain relief [analgesic]) 2. Surrogate end point (Predictive of the definitive end point  Reduction in tumor size[anticancer])
  • 51. Phase IIa • “Proof of concept”/ “Proof of claims” • Preliminary evidence of efficacy & safety • Up to 200 pts. are studied  Potential therapeutic benefits & side effects are observed • Establishment of dose range for more definitive therapeutic trials in phase IIb • Study design  Single blind (Subject unaware if he is taking placebo/positive control/new drug)
  • 52. Phase IIb • Dose-finding studies • To confirm efficacy with statistical significance • Determine the optimal dose & dosing regimen • Large no. of patients used (200-400) • Study design  Double blind (3rd party holds the code identifying each medication & this code is not deciphered until all clinical data has been coll.)
  • 53. Phase III • Large scale, multicentered randomized double blind trials to further establish safety & efficacy • Made using “Double-blind cross over” designs to minimize errors • NDA  After completion of phase III trials, sponsors file a “New Drug Application” with the drug control authorities of that country • NDS  If documentation is acceptable & in compliance, drug enters market with NDS
  • 54. Double blind Cross Over Design Pt. grp. (randomi zed) Week 1 Week 2 Week 3 I Standard drug Placebo New drug II Placebo New drug Standard drug III New drug Standard drug Placebo
  • 55. Phase IV • Surveillance phase during the post marketing clinical use of the drug • Used to discover • Relatively rare side effects • Previously unknown drug interaction • Previously unknown therapeutic use detected by a chance discovery
  • 56. Phase V • Aims to bridge the gap between basic and clinical research1 • Encompasses laboratory studies, clinical demands, public health and health management, policies and economics1 • Crucial in the evolution of contemporary biomedical science1 • It is used to signify the integration of a new clinical treatment into widespread public health practice2 1-Translational research: from benchside to bedside.N C Keramaris, N K Kanakaris, C Tzioupis, G Kontakis, P V Giannoudis Academic Department of Trauma and Orthopaedics, Leeds Teaching Hospitals, University of Leeds, Great George Street, Leeds LS1 3EX, UK.Injury (Impact Factor: 1.93). 07/2008; 39(6):643-50. DOI: 10.1016/j.injury.2008.01.051 Source: PubMed 2-Margaret A. Rogers (June 2009). "What are the phases of intervention research?". American Speech-Language-Hearing Association. Retrieved Jan 8, 2013.
  • 57. Preclinical safety assessment 1. Exploratory toxicology • Rough estimate of toxicity (2 weeks) • Provides an indication of main organs & physiological systems involved 2. Regulatory toxicology (GLP) • Reqd. by regulatory authorities/EC before compound can be given for 1st time to humans • Studies reqd. to support an application for marketing approval
  • 58. Timing of safety assessment
  • 59. Genotoxicity • Mutagenicity  Chemical alteration of DNA sufficient to cause abnormal gene expression in the affected cell & its offspring • Chromosomal damage • End results  Carcinogenesis & Teratogenicity (detected by long-term animal studies)
  • 60. Toxicokinetics “Generation of pharmacokinetic data, either as an integral component in the conduct of non-clinical toxicity studies, or in specially designed supportive studies, in order to assess systemic exposure” (ICH Guideline S3A) • Pharmacokinetics applied to toxicological studies
  • 61. Toxicity measures 1. NTEL  Largest dose in most sensitive species 2. LD50  Estimated dose reqd. to kill 50% expt. An. 3. NOAEL  Largest dose causing neither tissue toxicity nor undesirable physiological effects 4. MTD  Largest dose tested causing no obvious signs of ill-health 5. NOEL  Threshold for producing any observed pharmacological or toxic effect